Optimizes vaginal microbiota structure

Improves vaginal micro-ecological balance

Promotes production of beneficial metabolites

Significantly enhanced microbial diversity and reshaped the vaginal micro-ecosystem structure

Increased the relative abundance of beneficial Lactobacillus species and reestablishes dominant microbiota

Effectively reduced Candida positivity rates and lowered the recurrence risk of fungal vaginosis.

Verified through population trials to possess significant anti-vaginitis capabilities. Additionally, N13 effectively adheres to vaginal epithelial cells, inhibiting common pathogens such as Escherichia coli, Salmonella, and Staphylococcus aureus.

Demonstrates significant therapeutic effects against vaginitis and possesses the ability to prevent recurrence. It broadly and efficiently inhibits pathogens such as Candida albicans, Escherichia coli, Staphylococcus aureus, Gardnerella vaginalis, and Salmonella.

Produces metabolites including phosphoric acid, peptidoglycans, lactobacillin, reuterin, and hydrogen peroxide, aiding in the formation of spatial occupation and creation of a vaginal acidic environment. This inhibits pathogen proliferation and prevents pathogen adherence to vaginal epithelial cells. Results from mouse experiments confirm LR08's ability to improve vaginal health and effectively treat vaginitis.